glp-1 heart issues Receptor Agonists in Failure GLP-1RA in Different HFpEF Phenotypes

Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, Greig NH, Li Y, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ

The FDA approves a new obesity pill, giving patients another option The FDA approves a new obesity pill, giving patients another option The Food and Drug Administration has approved the second GLP-1 pill to treat obesity, this time from drugmaker Eli Lilly

doi: 10.1186/1471-2296-15-124

Why bother

Alopecia affects approximately 2.5% of BC patients, and about 8% discontinue AI therapy due to this adverse effect (Freites-Martinez et al., 2018

These patents, covering a broad family of derivative compounds of semaglutide, are conceived to prevent competitors from developing related drugs that could compete with Novo Nordisks products on the market